6-(3-(4-(O-METHOXYPHENYL)-1-PIPERAZINYL)PROPYLAMINO)-1,3-DIMETHYLURACIL
Cerebrovascular Disorders
The George Institute for Global Health, ChinaSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Cerebrovascular Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
WARFARIN Seoul National University Hospital | Phase 4 | BBB |
Acetylsalicylic Acid Peking Union Medical College Hospital | Phase 3 | BB |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Zhejiang Provincial People's Hospital | Phase 3 | BB |
Lipitor Sichuan Provincial People's Hospital | Phase 4 | BB |
Plavix Peking Union Medical College Hospital | Phase 3 | BB |
View all 37 →
Same molecule, other indications
6-(3-(4-(O-METHOXYPHENYL)-1-PIPERAZINYL)PROPYLAMINO)-1,3-DIMETHYLURACIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →